Bowel obstruction medical therapy

Bowel obstruction Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Bowel obstruction from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery Non-operative Management Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Bowel obstruction medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Bowel obstruction medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Bowel obstruction medical therapy
CDC on Bowel obstruction medical therapy
Bowel obstruction medical therapy in the news
Blogs on Bowel obstruction medical therapy
Directions to Hospitals Treating Bowel obstruction
Risk calculators and risk factors for Bowel obstruction medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]

Overview

The mainstay treatment of bowel obstruction is surgical and non-operative management. The role of medical therapy is supportive and is limited by palliative pain management in cancer patients, fluid and electrolyte replenishment, decreasing abdominal distension, peritumoral edema, intraluminal secretions, peristaltic movements, and control of nausea and vomiting.

Medical Therapy

The mainstay treatment of bowel obstruction is surgical and non-operative management. The role of medical therapy is supportive and is limited by control of vomiting and nausea, fluid and electrolyte replenishment, palliative pain management in cancer patients, decreasing abdominal distension, peritumoral edema, intraluminal secretions, and peristaltic movements.

• 1 Antiemetics
  • 1.1 Antiemetics in cancer patients
    • 1.1.1 Adult

      • Note (1): Used in conjunction with nasogastric decompression

      • Preferred regimen (1): Haloperidol 0.5 -2 mg and up to 20 mg PO q6h IV or SC
      • Preferred regimen (2): Dexamethasone 4 mg q12h IV or SC
      • Preferred regimen (3): Octreotide 0.1 mg and up to 0.3 mg q8h IV or SC
      • Alternative regimen (1): Hyoscine (scopolamine) hydrobromide 0.2 - 0.4 mg q6 - 8h SC or transdermal
      • Alternative regimen (2): Chlorpromazine, prochlorperazine, or cyclizine 0.2 - 0.4 mg q6 - 8h SC or IV or rectally
    • 1.1.2 Antiemetics in non-cancer patients
      • Preferred regimen (1): Promethazine 12.5-25 mg q4 - 6h PRN or PO, alternatively 12.5-25 mg q4 - 6h IV or IM
      • Preferred regimen (2): Ondansetron 4 - 8 mg q8-12hr PO or IV
    • 1.1.3 Pediatric
      • 1.1.3.1 Children 1 month - 12 years of age
        • Preferred regimen (1): Ondansetron <40 kg, 0.1 mg/kg IV
        • Preferred regimen (2): Ondansetron >40 kg, 4 mg IV
      • 1.1.3.1 Children < 2 years of age
        • Preferred regimen (1): Promethazine - contraindicated
      • 1.1.3.2 Children > 2 years of age
        • Preferred regimen (1): Promethazine 0.25-1 mg/kg PO/PR q4-6hr; not > 25 mg
      • 1.1.3.2 Children > 12 years of age
        • Preferred regimen (1): Ondansetron 4 mg IV/IM or 16 mg PO 1 hr
• 2 Fluid and electrolyte replacement
  • 2.1 Fluid replacement
    • 2.1.1 Adult
      • Parenteral regimen
        • Preferred regimen (1): Isotonic saline or lactated Ringer solution 1 - 2 L IV initially, in addition to administration of fluid equal to the urine output plus insensible fluid losses (approx. 30 - 50 ml)
    • 2.2 Electrolyte replacement
      • Hyponatremia
        • Preferred regimen (1): Sodium Potassium 40 mEq/L or 2.25 g per L
      • Hypokalemia

    Note (1): Replacement is only necessary if deficit continues for >48h, or in excess of 2L in 24h

    • • • Preferred regimen (1): Potassium 40 mEq/L or 3.0 g per L not > 80 mEq/L
      • Hypochloremia
        • Preferred regimen (1): Chloride 40 mEq/L not> 80 mEq/L
• 3 Pain management in cancer/non-cancer patients
  • 3.1 Non-opioids
    • 3.1.1 Adult
      • Parenteral regimen
        • Preferred regimen (1): Acetaminophen 325–1000 mg PO q4–6h PRN
        • Alternative regimen (2): Aspirin 325–650 mg PO q4h PRN
        • Alternative regimen (3): Diclofenac 50 mg PO BID-TID
        • Alternative regimen (3): Etodolac 200–400 mg PO q6–8h
        • Alternative regimen (4): Ibuprofen 400–600 mg POq 4–6h PRN
        • Alternative regimen (5): Indomethacin 25–50 mg PO TID
        • Alternative regimen (6): Ketoprofen 25–50 mg PO q6h–q8h
        • Alternative regimen (7): Ketorolac 10 mg PO q4–6h PRN or 30 mg IV/IM q6h
        • Alternative regimen (8): Meclofenamate 50–100 mg PO q4–6h PRN
        • Alternative regimen (9): Mefenamic acid 250 mg PO q4–6 PRN
        • Alternative regimen (10): Meloxicam 7.5–15 mg PO once daily
        • Alternative regimen (11): Nabumetone 100–2000 mg once daily
        • Alternative regimen (12): Naproxen 250–500 mg PO BID
        • Alternative regimen (13): Oxaprozin 1200 mg PO once daily
        • Alternative regimen (14): Piroxicam 20 mg PO once daily
        • Alternative regimen (15): Sulindac 150–200 mg PO BID
        • Alternative regimen (16): Tolmetin 200–600 mg PO BID-TID
        • Alternative regimen (17): Tramadol 50–100 mg PO q4–6h PRN; 100 – 300 mg QD for SR
        • Alternative regimen (18): Celecoxib 200 mg PO BID
  • 3.2 Opioids
    • • • Preferred regimen (1): Morphine sulfate 10–30 mg q3–4h PO
        • Alternative regimen (1.2): Rectal suppository; 10–20 mg q4h
        • Alternative regimen (1.3): PRN; 2.5–10 mg q2–6h
        • Alternative regimen (1.4): Epidural; 3–5 mg once, then 0.1–0.7 mg/hr
        • Alternative regimen (1.5): Intrathecal; start 100:1 IT-to-IV, then titrate to pain
        • Alternative regimen (1.6): Controlled release tab 15–30 mg q8–12h
        • Alternative regimen (1.7): Sustained release tab 15–30 mg q8–12h
        • Alternative regimen (1.8): Extended release capsule 20 mg q24h, may increase by 20 mg increments every other day
        • Alternative regimen (1.9): Extended release capsule 30 mg q24h, may increase by 30 mg increments q4days (max 1600 mg/d)
        • Alternative regimen (2): Codeine 15–60 mg q4–6h (max 60 mg/d)
        • Alternative regimen (3): Dilaudid 2–8 mg q3-4h for PO and PR
        • Alternative regimen (4): Roxycodone 5–30 mg q4h
        • Alternative regimen (5): Oxycontin 10–160 mg q12h
        • Alternative regimen (6): Opana 5–10 mg q4–6h
        • Alternative regimen (7): Opana extended release 5–40 mg q12h
        • Alternative regimen (8): Propoxyphene HCl 65 mg q4h (max 390 mg/24h)
        • Alternative regimen (9): Methadone 2.5–10 mg q3-6h

          • Note (1): Has very long half-life (8–60 hours)

        • Alternative regimen (10): Meperidine 50–150 mg q3–4h

          • Note (2): Decrease dose if given IV, administer slow or via PCA. Not recommended for chronic use.

        • Alternative regimen (11): Fentanyl 25–100 mcg q1–2h or 0.5–1.5 mcg/kg/hr IV infusion via PCA
        • Alternative regimen (12): Actiq; start with 200 mcg for breakthrough pain episodes, then titrate to pain
        • Alternative regimen (13): Duragesic 25 mcg/h q72hr, may increase q3–6days

References

Template:WikiDoc Sources